Effects of a propylene glycol-hydroxypropyl guar nanoemulsion in patients with mild to moderate dry eye disease
- PMID: 40694228
- DOI: 10.1007/s10792-025-03648-6
Effects of a propylene glycol-hydroxypropyl guar nanoemulsion in patients with mild to moderate dry eye disease
Abstract
Background: Dry eye disease (DED) is a common inflammatory disease of the eye surface that significantly affects quality of life. The present study investigated the effect of a propylene glycol-hydroxypropyl guar (PG-HPG) nanoemulsion on objective non-invasive ocular surface status markers in individuals with mild to moderate dry eye disease.
Methods: A nonrandomized clinical trial in fifty eyes from 25 healthy subjects with mild to moderate DED who applied one drop of PG-HPG nanoemulsion to each eye twice a day for three months. The primary outcomes measured changes in tear film osmolarity and meibography scores from baseline to three months.
Results: There were statistically significant changes in meibography scores (p < 0.0001) and osmolarity (p = 0.0066) from baseline to three months. The average osmolarity decreased by approximately 6.17 units from baseline to three months. No statistically significant changes were observed in NIAVG, Schirmer's test, or NIBUT from baseline to three months.
Conclusions: PG-HPG Nano-emulsion produced changes in objective non-invasive ocular surface status markers, including a reduction in meibography scores and tear film osmolarity at three months, further clinical studies on the effectiveness of PG-HPG against a comparator are to expand the evidence of its effectiveness as a therapeutic option and its effects on patient quality of life in DED management.
Keywords: Artificial tears; Dry eye disease; Meibography scores; Propylene glycol-hydroxypropyl guar; Tear film osmolarity.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no competing interests. Ethical approval: The study was conducted in accordance with the Declaration of Helsinki and approved by the Research Ethics Committee of the Centro de Retina Médica y Quirúrgica in Guadalajara Jalisco, México on July 3rd, 2023. Informed consent: Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.
References
-
- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK et al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276–283. https://doi.org/10.1016/j.jtos.2017.05.008 - DOI - PubMed
-
- Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F et al (2017) TFOS DEWS II epidemiology report. Ocul Surf 15:334–365. https://doi.org/10.1016/j.jtos.2017.05.003 - DOI - PubMed
-
- Miljanović B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 143:409–415. https://doi.org/10.1016/j.ajo.2006.11.060 - DOI - PubMed - PMC
-
- Gayton JL (2009) Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol 3:405–412. https://doi.org/10.2147/opth.s5555 - DOI - PubMed - PMC
-
- Pult H, Riede-Pult BH (2012) Non-contact meibography: keep it simple but effective. Cont Lens Anterior Eye 35:77–80. https://doi.org/10.1016/j.clae.2011.08.003 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
